Efecto de los inhibidores de la aromatasa en ciclos de estimulación de la ovulación en un programa de criopreservación de la fertilidad femenina
- Carmen Julia Rodríguez Izquierdo 1
- M.ª Carmen Gonzalvo López 1
- Ana Clavero Gilabert 1
- Noelia Morales Rincón 1
- Elena Fernández Sierra 1
- Noelia Sarasquete Martínez 1
- María José Lupiáñez Giner 1
- Alejandra Muñoz Oyonarte 1
- Bárbara Romero 1
- Rocío Sánchez 1
- José Antonio Castilla Alcalá 1
- 1 Unidad de Reproducción Humana. Hospital Universitario Virgen de las Nieves
ISSN: 2660-7484, 2660-7638
Année de publication: 2022
Volumen: 3
Número: 1
Pages: 3-11
Type: Article
D'autres publications dans: Revista de Medicina de Laboratorio
Résumé
Introduction: nowadays the increasing incidence of breast cancer and survival rates of breast cancer patients has led to an increment in the demand for female fertility cryopreservation programs. To increase the safety of these programs, it has been proposed to use aromatase inhibitor (AI) medications, which decrease the high levels of estrogen that are reached during ovulation stimulation. Material and methods: to assess the effect of aromatase inhibitors on the number and quality of oocytes obtained in ovarian stimulation cycles of women in fertility cryopreservation programs, a retrospective observational cohort study was performed with a sample of 112 women between 2009 and 2020. We compared a group of 59 women who received an aromatase inhibitor in the ovulation stimulation protocol against another group of 53 women which did not receive an aromatase inhibitor. Results: results obtained indicate that there are no statistically significant differences between the two groups in the percentage of cancelled cycles (6.8 % vs. 9.4 %), in the number of days of stimulation (11.0 ± 2,1 days vs. 11.6 ± 1.9 days), in the total number of oocytes (10 ± 6.4 oocytes vs. 10 ± 8.9 oocytes) nor the number of MII (8 ± 5.1 MII vs. 8.3 ± 7.2 MII). On the other hand, we found statistically significant differences in the serum estradiol concentration (66.1 ± 51.3 pg/mL vs. 280.7 ± 272.8 pg/mL, p < 0.001) and the FSH dose per number of oocytes obtained (307 ± 318.7 UI vs. 574.9 ± 796.6 UI, p < 0.05); both of them were significantly lower when letrozole was administered. Conclusion: therefore this study concluded that the inclusion of letrozole in female fertility cryopreservation protocols in women with breast cancer allows similar results to protocol not including letrozole in terms of oocyte quantity and quality, increasing the safety of such treatments in these women by reducing the mean serum concentration of estradiol.